Open Access
Volume 7, Number 4, December 2017
Article Number 23
Number of page(s) 12
Published online 13 November 2017
  1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108. [CrossRef]
  2. Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer. 1999; 83: 18-29. [CrossRef] [PubMed]
  3. Liaw YP, Huang YC, Lien GW. Patterns of lung cancer mortality in 23 countries: application of the age-period-cohort model. BMC Public Health. 2005; 5: 22. [CrossRef]
  4. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007; 57: 43-66. [CrossRef] [PubMed]
  5. Spira A,Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med. 2004; 350: 379-92. [CrossRef] [PubMed]
  6. Herbst RS, Bunn PA, Jr. Targeting the epidermal growth factor receptor in non-small cell lung cancer. Clin Cancer Res. 2003; 9: 5813-24. [PubMed]
  7. Broker LE, Glaccone G. The role of new agents in the treatment of non-small cell lung cancer. Eur J Cancer. 2002; 38: 2347-61. [CrossRef] [PubMed]
  8. Chen CJ, You SL, Lin LH, Hsu WL, Yang YW. Cancer epidemiology and control in Taiwan: a brief review. Jpn J Clin Oncol. 2002;32 Suppl: S66-81.
  9. Chen CJ, Liang KY, Chang AS, Chang YC, Lu SN, Liaw YF, et al. Effects of hepatitis B virus, alcohol drinking, cigarette smoking and familial tendency on hepatocellular carcinoma. Hepatology. 1991; 13: 398-406. [CrossRef] [PubMed]
  10. Lin TM, Yang CS, Tu SM, Chen CJ, Kuo KC, Hirayama T. Interaction of factors associated with cancer of the nasopharynx. Cancer. 1979; 44: 1419-23. [CrossRef] [PubMed]
  11. Hung HC, Chuang J, Chien YC, Chern HD, Chiang CP, Kuo YS, et al. Genetic polymorphisms of CYP2E1, GSTM1, and GSTT1; environmental factors and risk of oral cancer. Cancer Epidemiol Biomarkers Prev. 1997; 6: 901-5.
  12. Liaw KM, Chen CJ. Mortality attributable to cigarette smoking in Taiwan: a 12-year follow-up study. Tob Control. 1998;7: 141-8. [CrossRef] [PubMed]
  13. Peto R, Darby S, Deo H, Silcocks P, Whitley E, Doll R. Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. BMJ. 2000; 321: 323-9. [CrossRef]
  14. Wei Q, Cheng L, Amos CI, Wang LE, Guo Z, Hong WK, et al. Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiologic study. J Natl Cancer Inst. 2000; 92: 1764-72. [CrossRef]
  15. Ettinger DS. Overview and state of the art in the management of lung cancer. Oncology (Williston Park) 2004; 18: 3-9.
  16. Brambilla E, Travis WD, Colby TV, Corrin B, Shimosato Y. The new World Health Organization classification of lung tumours. Eur Respir J. 2001; 18: 1059-68. [CrossRef] [PubMed]
  17. Read WL, Page NC, Tierney RM, Piccirillo JF, Govindan R. The epidemiology of bronchioloalveolar carcinoma over the past two decades: analysis of the SEER database. Lung Cancer. 2004; 45: 137-42. [CrossRef] [PubMed]
  18. Beasley MB, Brambilla E, Travis WD. The 2004 World Health Organization classification of lung tumors. Semin Roentgenol. 2005; 40: 90-7. [CrossRef] [PubMed]
  19. Shinoura N, Yamada R, Okamoto K, Nakamura O, Shitara N. Local recurrence of metastatic brain tumor after stereotactic radiosur-gery or surgery plus radiation. J Neurooncol. 2002; 60: 71-7. [CrossRef] [PubMed]
  20. Lavine SD, Petrovich Z, Cohen-Gadol AA, Masri LS, Morton DL, O'Day SJ, et al. Gamma knife radiosurgery for metastatic melanoma: an analysis of survival, outcome, and complications. Neurosurgery. 1999; 44: 59-64; discussion 64-6. [CrossRef] [PubMed]
  21. Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med. 2005; 352: 2589-97. [CrossRef] [PubMed]
  22. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004; 350: 351-60. [CrossRef] [PubMed]
  23. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002; 346: 92-8. [CrossRef] [PubMed]
  24. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004; 22: 1589-97. [CrossRef] [PubMed]
  25. Mahalingam D, Mita A, Mita MM, Nawrocki ST, Giles FJ. Targeted therapy for advanced non-small cell lung cancers: historical perspective, current practices, and future development. Curr Probl Cancer. 2009; 33: 73-111. [CrossRef]
  26. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, et al. p53 status and the efficacy of cancer therapy in vivo. Science 1994; 266: 807-10. [CrossRef] [PubMed]
  27. Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M, Tanimoto M. Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2004; 22: 3852-9. [CrossRef] [PubMed]
  28. Ardizzoni A, Boni L, Tiseo M, Fossella FV, Schiller JH, Paesmans M, et al. Cisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst. 2007; 99: 847-57. [CrossRef]
  29. Le Chevalier T, Scagliotti G, Natale R, Danson S, Rosell R, Stahel R, et al. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer. 2005; 47: 69-80. [CrossRef] [PubMed]
  30. Cohen MH, Gootenberg J, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist. 2007; 12: 713-8. [CrossRef] [PubMed]
  31. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006; 355: 2542-50. [CrossRef] [PubMed]
  32. Muller M, Strand S, Hug H, Heinemann EM, Walczak H, Hofmann WJ, et al. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (ApO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J Clin Invest. 1997; 99: 403-13. [CrossRef]
  33. Fulda S, Friesen C, Debatin KM. Molecular determinants of apoptosis induced by cytotoxic drugs. Klinische Padiatrie. 1998; 210: 148-52. [CrossRef] [PubMed]
  34. Cho JY, Kim JH, Lee YH, Chung KY, Kim SK, Gong SJ, et al. Correlation between K-ras gene mutation and prognosis of patients with nonsmall cell lung carcinoma. Cancer. 1997; 79: 462-67. [CrossRef] [PubMed]
  35. Britten RA, Liu D, Tessier A, Hutchison MJ, Murray D. ERCC1 expression as a molecular marker of cisplatin resistance in human cervical tumor cells. Int J Cancer. 2000; 89: 453-57. [CrossRef] [PubMed]
  36. Cohen SM, Lippard SJ. Cisplatin: from DNA damage to cancer chemotherapy. Prog Nucleic Acid Res Mol Biol. 2001; 67: 93-130. [CrossRef] [PubMed]
  37. Kartalou M, Essigmann JM. Mechanisms of resistance to cisplatin. Mutat Res. 2001; 478: 23-43. [CrossRef]
  38. Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev. 2007; 33: 9-23. [CrossRef] [PubMed]
  39. Perez RP. Cellular and molecular determinants of cisplatin resistance. Eur J Cancer. 1998; 34: 1535-42. [CrossRef] [PubMed]
  40. Niedner H, Christen R, Lin X, Kondo A, Howell SB. Identification of genes that mediate sensitivity to cisplatin. Molecular Pharmacology. 2001; 60: 1153-60. [CrossRef] [PubMed]
  41. Mansouri A, Ridgway LD, Korapati AL, Zhang Q, Tian L, Wang Y, et al. Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells. J Biol Chem. 2003; 278: 19245-56. [CrossRef] [PubMed]
  42. Seve P, Dumontet C. Chemoresistance in non-small cell lung cancer. Curr Med Chem Anticancer Agents. 2005; 5: 73-88. [CrossRef] [PubMed]
  43. Rowinsky EK, Onetto N, Canetta RM, Arbuck SG. Taxol: the first of the taxanes, an important new class of antitumor agents. Semin Oncol. 1992; 19: 646-62. [PubMed]
  44. Eckardt JR. Antitumor activity of docetaxel. Am J Health Syst Pharm. 1997; 54: S2-6. [PubMed]
  45. Neuss N, Mallett GE, Brannon DR, Mabe JA, Horton HR, Huck-step LL. Vinca alkaloids XXXIII [1]. Microbiological conversions of vincaleukoblastine (VLB, vinblastine), an antitumor alkaloid from Vinca rosea. Linn. Helv Chim Acta. 1974; 57: 1886-90. [CrossRef]
  46. TerHaar E, Kowalski RJ, Hamel E, Lin CM, Longley RE, Gunasek-era SP, et al. Discodermolide, a cytotoxic marine agent that stabilizes microtubules more potently than taxol. Biochemistry. 1996; 35: 243-50. [CrossRef] [PubMed]
  47. Gligorov J, Lotz JP. Preclinical pharmacology of the taxanes: Implications of the differences. Oncologist. 2004; 9: 3-8. [CrossRef] [EDP Sciences]
  48. Chang AY, Kim K, Glick J, Anderson T, Karp D, Johnson D. Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: The Eastern Cooperative Oncology Group Results. J Natl Cancer Inst. 1993; 85: 388-94. [CrossRef]
  49. Murphy WK, Fossella FV, Winn RJ, Shin DM, Hynes HE, Gross HM, et al. Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst. 1993; 85: 384-8. [CrossRef]
  50. Gatzemeier U, Heckmayer M, Neuhauss R, Schluter I, von Pawel J, Wagner H, et al. Chemotherapy of advanced inoperable non-small cell lung cancer with paclitaxel: a phase II trial. Semin Oncol. 1995; 22: 24-8.
  51. Millward MJ, Bishop JF, Friedlander M, Levi JA, Goldstein D, Olver IN, et al. Phase II trial of a 3-hour infusion of paclitaxel in previously untreated patients with advanced non-small-cell lung cancer. J Clin Oncol. 1996; 14: 142-8. [CrossRef] [PubMed]
  52. Haldar S, Basu A, Croce CM. Bcl2 is the guardian of microtubule integrity. Cancer Res. 1997; 57: 229-33.
  53. Hennequin C, Giocanti N, Favaudon V. S-phase specificity of cell killing by docetaxel (Taxotere) in synchronised HeLa cells. Br J Cancer. 1995; 71: 1194-8. [CrossRef] [PubMed]
  54. Pasquier E, Carre M, Pourroy B, Camoin L, Rebai O, Briand C, et al. Antiangiogenic activity of paclitaxel is associated with its cyto-static effect, mediated by the initiation but not completion of a mi-tochondrial apoptotic signaling pathway. Mol Cancer Ther. 2004; 3: 1301-10. [PubMed]
  55. Bava SV, Puliappadamba VT, Deepti A, Nair A, Karunagaran D, Anto RJ. Sensitization of taxol-induced apoptosis by curcumin involves down-regulation of nuclear factor-kappaB and the serine/ threonine kinase Akt and is independent of tubulin polymerization. J Biol Chem. 2005; 280: 6301-8. [CrossRef] [PubMed]
  56. Subbaramaiah K, Hart JC, Norton L, Dannenberg AJ. Microtubule-interfering agents stimulate the transcription of cyclooxygenase-2. Evidence for involvement of ERK1/2 AND p38 mitogen-activated protein kinase pathways. J Biol Chem. 2000; 275: 14838-45. [CrossRef] [PubMed]
  57. Wang TH, Wang HS, Soong YK. Paclitaxel-induced cell death: where the cell cycle and apoptosis come together. Cancer. 2000; 88: 2619-28. [CrossRef] [PubMed]
  58. Wang LG, Liu XM, Kreis W, Budman DR. The effect of antimi-crotubule agents on signal transduction pathways of apoptosis: a review. Cancer Chemother Pharmacol. 1999; 44: 355-61. [CrossRef]
  59. Li H, Zhu H, Xu CJ, Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell. 1998; 94: 491-501. [CrossRef]
  60. Ofir R, Seidman R, Rabinski T, Krup M, Yavelsky V, Weinstein Y, et al. Taxol-induced apoptosis in human SKOV3 ovarian and MCF7 breast carcinoma cells is caspase-3 and caspase-9 independent. Cell Death Differ. 2002; 9: 636-42. [CrossRef]
  61. Ibrado AM, Liu L, Bhalla K. Bcl-xL overexpression inhibits progression of molecular events leading to paclitaxel-induced apop-tosis of human acute myeloid leukemia HL-60 cells. Cancer Res. 1997; 57: 1109-15.
  62. Perkins C, Kim CN, Fang G, Bhalla KN. Arsenic induces apop-tosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L). Blood. 2000; 95: 1014-22.
  63. Park SJ, Wu CH, Gordon JD, Zhong X, Emami A, Safa AR. Taxol induces caspase-10-dependent apoptosis. J Biol Chem. 2004; 279: 51057-67. [CrossRef] [PubMed]
  64. Lin HL, Liu TY, Chau GY, Lui WY, Chi CW. Comparison of 2-methoxyestradiol-induced, docetaxel-induced, and paclitaxel-induced apoptosis in hepatoma cells and its correlation with reactive oxygen species. Cancer. 2000; 89: 983-94. [CrossRef] [PubMed]
  65. Mason KA, Hunter NR, Milas M, Abbruzzese JL, Milas L. Do-cetaxel enhances tumor radioresponse in vivo. Clin Cancer Res. 1997; 3: 2431-8. [PubMed]
  66. Milas L, Milas MM, Mason KA. Combination of taxanes with radiation: preclinical studies. Semin Radiat Oncol. 1999; 9: 12-26. [PubMed]
  67. Mason K, Staab A, Hunter N, McBride W, Petersen S, Terry N, et al. Enhancement of tumor radioresponse by docetaxel: Involvement of immune system. Int J Oncol. 2001; 18: 599-606. [PubMed]
  68. Olijslagers SJ, Zhang YH, Backendorf C, Noteborn MH. Additive cytotoxic effect of apoptin and chemotherapeutic agents paclitaxel and etoposide on human tumour cells. Basic Clin Pharmacol Toxicol. 2007; 100: 127-31.
  69. Juretic A, Sobat H, Samija M. Combined modality therapy of non-small cell lung cancers. Ann Oncol. 1999; 10 Suppl 6: 93-8. [CrossRef] [PubMed]
  70. Belani CP. Paclitaxel and docetaxel combinations in non-small cell lung cancer. Chest. 2000; 117:144S-51S. [CrossRef] [PubMed]
  71. Suzuki A, Kawabata T, Kato M. Necessity of interleukin-1beta converting enzyme cascade in taxotere-initiated death signaling. Eur J Pharmacol. 1998; 343: 87-92. [CrossRef] [PubMed]
  72. Ganansia-Leymarie V, Bischoff P, Bergerat JP, Holl V. Signal transduction pathways of taxanes-induced apoptosis. Curr Med Chem Anticancer Agents. 2003; 3: 291-306. [CrossRef] [PubMed]
  73. Kottke TJ, Blajeski AL, Meng XW, Svingen PA, Ruchaud S, Mesner PW Jr., et al. Lack of correlation between caspase activation and caspase activity assays in paclitaxel-treated MCF-7 breast cancer cells. J Biol Chem. 2002; 277: 804-15. [CrossRef] [PubMed]
  74. Lee SJ, Lee HS, Choi JS, Na JO, Seo KH, Oh MH, et al. Remarkable Effect of Gefitinib Retreatment in a Lung Cancer Patient With Lepidic Predominat Adenocarcinoma who had Experienced Favorable Results From Initial Treatment With Gefitinib: A Case Report. J Clin Med Res. 2012; 4: 216-20. [PubMed]
  75. Meric JB, Faivre S, Monnerat C, Adi Vago N, Le Chevalier T, Armand JP, et al. [Zd 1839 “Iressa"]. Bull Cancer. 2000; 87: 873-6. [PubMed]
  76. Anderson NG, Ahmad T, Chan K, Dobson R, Bundred NJ. ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression. Int J Cancer. 2001; 94: 774-82. [CrossRef] [PubMed]
  77. Baselga J, Rischin D, Ranson M, Calvert H, Raymond E, Kieback DG, et al. Phase I safety, pharmacokinetic, and pharma-codynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol. 2002; 20: 4292-302. [CrossRef] [PubMed]
  78. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol. 2003; 21: 2237-46. [CrossRef] [PubMed]
  79. Kris MG, Natale RB, Herbst RS, Lynch TJ Jr., Prager D, Belani CP, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA. 2003; 290: 2149-58. [CrossRef] [PubMed]
  80. von Minckwitz G, Jonat W, Fasching P, du Bois A, Kleeberg U, Luck HJ, et al. A multicentre phase II study on gefitinib in taxane-and anthracycline-pretreated metastatic breast cancer. Breast Cancer Res Treat. 2005; 89: 165-72. [CrossRef] [PubMed]
  81. Schiff BA, McMurphy AB, Jasser SA, Younes MN, Doan D, Yigitbasi OG, et al. Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer. Clin Cancer Res. 2004; 10: 8594-602. [CrossRef] [PubMed]
  82. Shi L, Tang J, Tong L, Liu Z. Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: a systematic review and meta-analysis of clinical trials. Lung Cancer. 2014; 83: 231-9. [CrossRef] [PubMed]
  83. Shi Y, Sun Y, Yu J, Ding C, Wang Z, Wang C, et al. China experts consensus on the diagnosis and treatment of advanced stage primary lung cancer (2016 version). Asia Pac J Clin Oncol. 2017; 13: 87-103. [CrossRef] [PubMed]
  84. Han SY, Zhao MB, Zhuang GB, Li PP. Marsdenia tenacissima extract restored gefitinib sensitivity in resistant non-small cell lung cancer cells. Lung Cancer. 2012; 75: 30-7. [CrossRef] [PubMed]
  85. Grigoriu B, Berghmans T, Meert AP. Management of EGFR mutated nonsmall cell lung carcinoma patients. Eur Respir J. 2015; 45: 1132-41. [CrossRef]
  86. Dhillon S. Gefitinib: a review of its use in adults with advanced non-small cell lung cancer. Target Oncol. 2015; 10: 153-70. [CrossRef]
  87. Li F, Zhu T, Cao B, Wang J, Liang L. Apatinib enhances antitu-mour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance. Eur J Cancer. 2017; 84: 184-92. [CrossRef] [PubMed]
  88. Abbruzzese JL, Grunewald R, Weeks EA, Gravel D, Adams T, Nowak B, et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol. 1991; 9: 491-8. [CrossRef] [PubMed]
  89. Csoka K, Liliemark J, Larsson R, Nygren P. Evaluation of the cytotoxic activity of gemcitabine in primary cultures of tumor cells from patients with hematologic or solid tumors. Semin Oncol. 1995; 22: 47-53.
  90. Pollera CF, Ceribelli A, Crecco M, Oliva C, Calabresi F. Prolonged infusion gemcitabine: a clinical phase I study at low-(300 mg/m2) and high-dose (875 mg/m2) levels. Invest New Drugs. 1997; 15: 115-21. [CrossRef]
  91. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012; 62: 220-41. [CrossRef] [PubMed]
  92. Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet. 2011; 378: 607-20. [CrossRef] [PubMed]
  93. Paez D, Labonte MJ, Lenz HJ. Pancreatic cancer: medical management (novel chemotherapeutics). Gastroenterol Clin North Am. 2012; 41: 189-209. [CrossRef] [PubMed]
  94. Heinemann V. Gemcitabine in the treatment of advanced pancreatic cancer: a comparative analysis of randomized trials. Semin Oncol. 2002; 29: 9-16. [CrossRef] [EDP Sciences] [PubMed]
  95. Erten C, Demir L, Somali I, Alacacioglu A, Kucukzeybek Y, Akyol M, et al. Cisplatin plus gemcitabine for treatment of breast cancer patients with brain metastases; a preferential option for triple negative patients? Asian Pac J Cancer Prev. 2013; 14: 3711-7. [CrossRef] [PubMed]
  96. Franchina T, Adamo B, Ricciardi GR, Caristi N, Agostino RM, Proto C, et al. Activity of pegylated liposomal doxorubicin in combination with gemcitabine in triple negative breast cancer with skin involvement: two case reports. Cancer Biol Ther. 2012; 13: 472-6. [CrossRef]
  97. Kim M, Chin YW, Lee EJ. alpha, gamma-Mangostins Induces Autophagy and Shows Synergistic Effectwith Gemcitabine in Pancreatic Cancer Cell Lines. Biomol Ther. (Seoul) 2017.
  98. Herrmann R, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schuller J, et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol. 2007; 25: 2212-7. [CrossRef] [PubMed]
  99. Heinemann V, Quietzsch D, Gieseler F, Gonnermann M, Schonekas H, Rost A, et al. Randomized phase III trial of gemcit-abine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol. 2006; 24: 3946-52. [CrossRef] [PubMed]
  100. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007; 25: 1960-6. [CrossRef] [PubMed]
  101. Wang Y, Schmid-Bindert G, Zhou C. Erlotinib in the treatment of advanced non-small cell lung cancer: an update for clinicians. Ther Adv Med Oncol. 2012; 4: 19-29. [CrossRef] [PubMed]
  102. Abera MB, Kazanietz MG. Protein kinase Calpha mediates erlo-tinib resistance in lung cancer cells. Mol Pharmacol. 2015; 87: 832-41. [CrossRef]
  103. Zhao J, Guerrero A, Kelnar K, Peltier HJ, Bader AG. Synergy between next generation EGFR tyrosine kinase inhibitors and miR-34a in the inhibition of non-small cell lung cancer. Lung Cancer. 2017; 108: 96-102. [CrossRef] [PubMed]
  104. Lee CB, Stinchcombe TE, Rosenman JG, Socinski MA. Therapeutic advances in local-regional therapy for stage III non-small-cell lung cancer: evolving role of dose-escalated conformal (3-dimen-sional) radiation therapy. Clin Lung Cancer. 2006; 8: 195-202. [CrossRef] [PubMed]
  105. Roswit B, Patno ME, Rapp R, Veinbergs A, Feder B, Stuhlbarg J, et al. The survival of patients with inoperable lung cancer: a large-scale randomized study of radiation therapy versus placebo. Radiology. 1968; 90: 688-97. [CrossRef] [PubMed]
  106. Johnson DH, Einhorn LH, Bartolucci A, Birch R, Omura G, Perez CA, et al. Thoracic radiotherapy does not prolong survival in patients with locally advanced, unresectable non-small cell lung cancer. Ann Intern Med. 1990; 113: 33-8. [CrossRef] [PubMed]
  107. Dillman RO, Berry C, Ryan KP, Green MR, Seagren SL. Recent outcomes for patients with carcinoma of the lung. Cancer Invest. 1991; 9: 9-17. [CrossRef] [PubMed]
  108. Payne DG. Non-small-cell lung cancer: should unresectable stage III patients routinely receive high-dose radiation therapy? J Clin Oncol. 1988; 6: 552-8. [CrossRef] [PubMed]
  109. Jung JW, Hwang SY, Hwang JS, Oh ES, Park S, Han IO. Ionising radiation induces changes associated with epithelial-mesenchymal transdifferentiation and increased cell motility of A549 lung epithelial cells. Eur J Cancer. 2007; 43: 1214-24. [CrossRef] [PubMed]
  110. Wild-Bode C, Weller M, Rimner A, Dichgans J, Wick W. Sublethal irradiation promotes migration and invasiveness of glioma cells: implications for radiotherapy of human glioblastoma. Cancer Res. 2001; 61: 2744-50.
  111. Camphausen K, Moses MA, Beecken WD, Khan MK, Folkman J, O'Reilly MS. Radiation therapy to a primary tumor accelerates metastatic growth in mice. Cancer Res. 2001; 61: 2207-11.
  112. Giaccone G. Clinical impact of novel treatment strategies. Onco-gene. 2002; 21: 6970-81. [CrossRef]
  113. Marino P, Preatoni A, Cantoni A. Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer. A meta-analysis. Cancer. 1995; 76: 593-601.
  114. Sause WT, Scott C, Taylor S, Johnson D, Livingston R, Komaki R, et al. Radiation Therapy Oncology Group (RT0G) 88-08 and Eastern Cooperative Oncology Group (EC0G) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst. 1995; 87: 198-205. [CrossRef]
  115. Zhang T, Cui GB, Zhang J, Zhang F, Zhou YA, Jiang T, et al. Inhibition of PI3 kinases enhances the sensitivity of non-small cell lung cancer cells to ionizing radiation. Oncol Rep. 2010; 24: 1683-9.
  116. Park SY, Kim YM, Pyo H. Gefitinib radiosensitizes non-small cell lung cancer cells through inhibition of ataxia telangiectasia mutated. Mol Cancer. 2010; 9: 222. [CrossRef] [PubMed]
  117. Hsiao WL, Liu L. The role of traditional Chinese herbal medicines in cancer therapy--from TCM theory to mechanistic insights. Plan-ta Med. 2010; 76: 1118-31. [CrossRef]
  118. Harvey AL, Cree IA. High-throughput screening of natural products for cancer therapy. Planta Med. 2010; 76: 1080-6. [CrossRef] [PubMed]
  119. Aravindaram K, Yang NS. Anti-inflammatory plant natural products for cancer therapy. Planta Med. 2010; 76: 1103-17. [CrossRef] [PubMed]
  120. Meijer L, Borgne A, Mulner O, Chong JP, Blow JJ, Inagaki N, et al. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem. 1997; 243: 527-36. [CrossRef] [PubMed]
  121. Tirado OM, Mateo-Lozano S, Notario V. Roscovitine is an effective inducer of apoptosis of Ewing’s sarcoma family tumor cells in vitro and in vivo. Cancer Res. 2005; 65: 9320-7. [CrossRef]
  122. Mohapatra S, Chu B, Zhao X, Pledger WJ. Accumulation of p53 and reductions in XIAP abundance promote the apoptosis of prostate cancer cells. Cancer Res. 2005; 65: 7717-23. [CrossRef]
  123. Lacrima K, Valentini A, Lambertini C, Taborelli M, Rinaldi A, Zucca E, et al. In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas. Ann Oncol. 2005; 16: 1169-76. [CrossRef] [PubMed]
  124. Zhang F, Zhang T, Gu ZP, Zhou YA, Han Y, Li XF, et al. Enhancement of radiosensitivity by roscovitine pretreatment in human non-small cell lung cancer A549 cells. J Radiat Res. (Tokyo) 2008; 49: 541-8. [CrossRef]
  125. Zhang F, Zhang T, Jiang T, Zhang R, Teng ZH, Li C, et al. Wort-mannin potentiates roscovitine-induced growth inhibition in human solid tumor cells by repressing PI3K/Akt pathway. Cancer Lett. 2009; 286: 232-9. [CrossRef]
  126. Park SE, Yoo HS, Jin CY, Hong SH, Lee YW, Kim BW, et al. Induction of apoptosis and inhibition of telomerase activity in human lung carcinoma cells by the water extract of Cordyceps militaris. Food Chem Toxicol. 2009; 47: 1667-75. [CrossRef] [PubMed]
  127. McCubrey JA, Lertpiriyapong K, Steelman LS, Abrams SL, Yang LV, Murata RM, et al. Effects of resveratrol, curcumin, ber-berine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs. Aging (Albany NY) 2017; 9: 1477-536.
  128. Aggarwal BB, Bhardwaj A, Aggarwal RS, Seeram NP, Shishodia S, Takada Y. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res. 2004; 24: 2783-840. [PubMed]
  129. Soleas GJ, Diamandis EP, Goldberg DM. Resveratrol: a molecule whose time has come? And gone? Clin Biochem. 1997; 30: 91-113. [CrossRef]
  130. Smoliga JM, Baur JA, Hausenblas HA. Resveratrol and health--a comprehensive review of human clinical trials. Mol Nutr Food Res. 2011; 55: 1129-41. [CrossRef] [PubMed]
  131. Athar M, Back JH, Tang X, Kim KH, Kopelovich L, Bickers DR, et al. Resveratrol: a review of preclinical studies for human cancer prevention. Toxicol Appl Pharmacol. 2007; 224: 274-83. [CrossRef] [PubMed]
  132. Stef G, Csiszar A, Lerea K, Ungvari Z, Veress G. Resveratrol inhibits aggregation of platelets from high-risk cardiac patients with aspirin resistance. J Cardiovasc Pharmacol. 2006; 48: 1-5. [CrossRef] [EDP Sciences] [PubMed]
  133. Bhat KPL, Kosmeder JW, 2nd, Pezzuto JM. Biological effects of resveratrol. Antioxid Redox Signal. 2001; 3: 1041-64. [CrossRef]
  134. Whyte L, Huang YY, Torres K, Mehta RG. Molecular mechanisms of resveratrol action in lung cancer cells using dual protein and microarray analyses. Cancer Res. 2007; 67: 12007-17. [CrossRef]
  135. Kim YA, Lee WH, Choi TH, Rhee SH, Park KY, Choi YH. Involvement of p21WAF1/CIp1, pRB, Bax and NF-kappaB in induction of growth arrest and apoptosis by resveratrol in human lung carcinoma A549 cells. Int J Oncol. 2003; 23: 1143-9. [PubMed]
  136. Patel KR, Brown VA, Jones DJ, Britton RG, Hemingway D, Miller AS, et al. Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. Cancer Res. 2010; 70: 7392-9. [CrossRef]
  137. Zhu J, Song X, Lin HP, Young DC, Yan S, Marquez VE, et al. Using cyclooxygenase-2 inhibitors as molecular platforms to develop a new class of apoptosis-inducing agents. J Natl Cancer Inst. 2002; 94: 1745-57. [CrossRef]
  138. Zhu J, Huang JW, Tseng PH, Yang YT, Fowble J, Shiau CW, et al. From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors. Cancer Res. 2004; 64: 4309-18. [CrossRef]
  139. Kucab JE, Lee C, Chen CS, Zhu J, Gilks CB, Cheang M, et al. Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours. Breast Cancer Res. 2005; 7:R796-807. [CrossRef]
  140. Tong Z, Wu X, Chen CS, Kehrer JP. Cytotoxicity of a non-cy-clooxygenase-2 inhibitory derivative of celecoxib in non-small-cell lung cancer A549 cells. Lung Cancer. 2006; 52: 117-24. [CrossRef] [PubMed]
  141. Tan YH, Lee KH, Lin T, Sun YC, Hsieh-Li HM, Juan HF, et al. Cytotoxicity and proteomics analyses of OSU03013 in lung cancer. Clin Cancer Res. 2008; 14: 1823-30. [CrossRef] [PubMed]
  142. Lu J, Papp LV, Fang J, Rodriguez-Nieto S, Zhivotovsky B, Holmgren A. Inhibition of Mammalian thioredoxin reductase by some flavonoids: implications for myricetin and quercetin antican-cer activity. Cancer Res. 2006; 66: 4410-8. [CrossRef]
  143. Zhang Q, Zhao XH, Wang ZJ. Flavones and flavonols exert cy-totoxic effects on a human oesophageal adenocarcinoma cell line (OE33) by causing G2/M arrest and inducing apoptosis. Food Chem Toxicol. 2008; 46: 2042-53. [CrossRef] [PubMed]
  144. Nadova S, Miadokova E, Cipak L. Flavonoids potentiate the efficacy of cytarabine through modulation of drug-induced apoptosis. Neoplasma. 2007; 54: 202-6. [PubMed]
  145. Wang ZH, Kang KA, Zhang R, Piao MJ, Jo SH, Kim JS, et al. Myricetin suppresses oxidative stress-induced cell damage via both direct and indirect antioxidant action. Environ Toxicol Phar. 2010; 29: 12-18. [CrossRef]
  146. Shvarev IF, Tsetlin AL. [Anti-blastic properties of berberine and its derivatives]. Farmakol Toksikol 1972; 35: 73-5. [PubMed]
  147. Ikram M.A. review on the chemical and pharmacological aspects of genus Berberis. Planta Med. 1975; 28: 353-8. [CrossRef] [PubMed]
  148. Creasey WA. Biochemical effects of berberine. Biochem Pharmacol. 1979; 28: 1081-4. [CrossRef] [PubMed]
  149. Ivanovska N, Philipov S. Study on the anti-inflammatory action of Berberis vulgaris root extract, alkaloid fractions and pure alkaloids. Int J Immunopharmacol. 1996; 18: 553-61. [CrossRef]
  150. Peng PL, Hsieh YS, Wang CJ, Hsu JL, Chou FP. Inhibitory effect of berberine on the invasion of human lung cancer cells via decreased productions of urokinase-plasminogen activator and matrix metalloproteinase-2. Toxicol Appl Pharmacol. 2006; 214: 8-15. [CrossRef] [PubMed]
  151. Jin P, Zhang C, Li N. Berberine exhibits antitumor effects in human ovarian cancer cells. Anticancer Agents Med Chem. 2015; 15: 511-6. [CrossRef]
  152. Wang K, Zhang C, Bao J, Jia X, Liang Y, Wang X, et al. Synergistic chemopreventive effects of curcumin and berberine on human breast cancer cells through induction of apoptosis and autophagic cell death. Sci Rep. 2016; 6: 26064. [CrossRef] [PubMed]
  153. Lee TH, Lee CK, Tsou WL, Liu SY, Kuo MT, Wen WC. A new cytotoxic agent from solid-state fermented mycelium of Antrodia camphorata. Planta Med. 2007; 73: 1412-5. [CrossRef] [PubMed]
  154. Kumar VB, Yuan TC, Liou JW, Yang CJ, Sung PJ, Weng CF. An-troquinonol inhibits NSCLC proliferation by altering PI3K/mT0R proteins and miRNA expression profiles. Mutat Res. 2011; 707: 42-52. [CrossRef]
  155. Chiang PC, Lin SC, Pan SL, Kuo CH, Tsai IL, Kuo MT, et al. Antroquinonol displays anticancer potential against human hepato-cellular carcinoma cells: a crucial role of AMPK and mT0R pathways. Biochem Pharmacol 2010; 79: 162-71. [CrossRef] [PubMed]
  156. Yu CC, Chiang PC, Lu PH, Kuo MT, Wen WC, Chen P, et al. Antroquinonol, a natural ubiquinone derivative, induces a cross talk between apoptosis, autophagy and senescence in human pancreatic carcinoma cells. J Nutr Biochem. 2012; 23: 900-7. [CrossRef]
  157. Lin HC, Lin MH, Liao JH, Wu TH, Lee TH, Mi FL, et al. Antroquinonol, a Ubiquinone Derivative from the Mushroom Antrodia camphorata, Inhibits Colon Cancer Stem Cell-like Properties: Insights into the Molecular Mechanism and Inhibitory Targets. J Agric Food Chem. 2017; 65: 51-59. [CrossRef] [PubMed]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.